From the publishers of JADPRO
Updates for the Advanced Practitioner
HER2-Positive Breast Cancer
Subscribe
About
Contact
MENU
Home
Visit JADPRO Online
In The News
In The Literature
Videos
More Updates
Advertisement
In The Literature
JAMA Oncol
Adjuvant Capecitabine in Combination With Docetaxel, Epirubicin, and Cyclophosphamide for Early Breast Cancer: The Randomized Clinical FinXX Trial
Eur J Cancer
Long-term Outcome of the REMAGUS 02 Trial, a Multicenter Randomised Phase II Trial in Locally Advanced Breast Cancer Patients Treated With Neoadjuvant Chemotherapy With or Without Celecoxib or Trastuzumab According to HER2 Status
BMJ Open
Efficacy and Safety of Lapatinib and Trastuzumab for HER2-Positive Breast Cancer: a Systematic Review and Meta-Analysis of Randomised Controlled Trials
JAMA Oncol
Brain Metastases in Newly Diagnosed Breast Cancer: A Population-Based Study
BMC Cancer
Development of a Test that Measures Real-Time HER2 Signaling Function in Live Breast Cancer Cell Lines and Primary Cells
Ann Surg Oncol
Results of a Phase Ib Trial of Combination Immunotherapy With a CD8+ T Cell Eliciting Vaccine and Trastuzumab in Breast Cancer Patients
Eur J Surg Oncol
Standardization of Oncoplastic Breast Conserving Surgery
Cancer Res
IL6 Signaling in Peripheral Blood T Cells Predicts Clinical Outcome in Breast Cancer
Breast Cancer Res
Phase II, Randomized, Placebo-Controlled Study of Dovitinib in Combination with Fulvestrant in Postmenopausal Patients with HR2-positive, HER2-negative Breast Cancer That Had Progressed During or After Prior Endocrine Therapy
Oncotarget
Pathological Complete Response of HER2-Positive Breast Cancer to Trastuzumab and Chemotherapy Can Be Predicted by HSD17B4 Methylation
J Transl Med
Association of Osteopontin With Specific Prognostic Factors and Survival in Adjuvant Breast Cancer Trials of the Hellenic Cooperative Oncology Group
Ther Adv Med Oncol
Progress With Palbociclib in Breast Cancer: Latest Evidence and Clinical Considerations
Breast Cancer Res Treat
Clinical Tumor Stage is the Most Important Predictor of Pathological Complete Response Rate After Neoadjuvant Chemotherapy in Breast Cancer Patients
Breast Cancer Res Treat
Multicenter Analysis of Neoadjuvant Docetaxel, Carboplatin, and Trastuzumab (TCH) in Patients With HER2-Positive Breast Cancer
Clin Cancer Res
Phase 1 Study of ONT-380, a HER2 Inhibitor, in Patients With HER2-Positive Advanced Solid Tumors, with an Expansion Cohort in HER2-Positive Metastatic Breast Cancer (MBC)
Breast Cancer Res
18FDG-PET/CT for Predicting the Outcome in ER-Positive/HER2-Negative Breast Cancer Patients: Comparison of Clinicopathological Parameters and PET Image-Derived Indices Including Tumor Texture Analysis
Ann Oncol
Incidence and Management of Diarrhea in Patients With HER2-Positive Breast Cancer Treated With Pertuzumab
Breast Cancer
Complete Remission in Metastatic Breast Cancer: Expecting the Unexpected
Breast
pCR Rates in Patients With Bilateral Breast Cancer After Neoadjuvant Anthracycline-Taxane Based-Chemotherapy. A Retrospective Pooled Analysis of Individual Patient Data From Four German Neoadjuvant Trials
Drugs Real World Outcomes
HER2-Positive Metastatic Breast Cancer Patients Receiving Pertuzumab in a Community Oncology Practice Setting: Treatment Patterns and Outcomes
N Engl J Med
Breast-Cancer Tumor Size, Overdiagnosis, and Mammography Screening Effectiveness
J Clin Oncol
Obesity and Breast Cancer Prognosis: Evidence, Challenges, and Opportunities
Endcocr Rel Cancer
ErbB-2 Nuclear Function in Breast Cancer Growth, Metastasis and Resistance to Therapy
FASEB J
Prognostic Impact of Total and Tyrosine Phosphorylated GIV/Girdin in Breast Cancers
Oncotarget
The Associations Between Mast Cell Infiltration, Clinical Features and Molecular Types of Invasive Breast Cancer
Practice Update
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
J Clin Oncol
Protein Intake and Breast Cancer Survival in the Nurses’ Health Study
BMC Cancer
Decreased Expression of Stomatin Predicts Poor Prognosis in HER2-Positive Breast Cancer
Oncology Letters
Trastuzumab as a Preoperative Monotherapy Does Not Inhibit HER2 Downstream Signaling in HER2-Positive Breast Cancer
Breast Cancer Research and Treatment
Inhibition of 6-Phosphofructo-2-kinase (PFKFB3) Suppresses Glucose Metabolism and the Growth of HER2+ Breast Cancer
Cancer Science
CITED2 in Breast Carcinoma as a Potent Prognostic Predictor Associated With Proliferation, Migration, and Chemoresistance
Oncogenesis
Loss of the Oncogenic Phosphatase PRL-3 Promotes a TNF-R1 Feedback Loop That Mediates Triple-Negative Breast Cancer
Oncotarget
MicroRNA-224 Inhibits Proliferation and Migration of Breast Cancer Cells by Down-Regulating Fizzled 5 Expression
New England Journal of Medicine
Adaptive Randomization of Neratinib in Early Breast Cancer
Clinical Breast Cancer
Dual Blockade of HER-2 Provides a Greater Magnitude of Benefit in Patients With Hormone-Negative Versus Hormone-Positive Breast Cancer
BioMed Central Cancer
Prognostic Impact of AJCC Response Criteria for Neoadjuvant Chemotherapy in Stage II/III Breast Cancer Patients: Breast Cancer Subtype Analyses
JAMA Oncology
Neoadjuvant Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer: A Systematic Review and Meta-analysis
European Journal of Cancer
HannaH Phase III Randomised Study: Association of Total Pathological Complete Response With Event-Free Survival in HER2-Positive Early Breast Cancer Treated With Neoadjuvant-Adjuvant Trastuzumab After 2 Years of Treatment-Free Follow-up
Journal of Clinical Oncology
Phase III Trial Evaluating Letrozole as First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor–Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance)
The Lancet Oncology
Neoadjuvant Nab-Paclitaxel in Breast Cancer: Trial Results and Patient Care
Pathology International
The Assessment of HER2 Status in Breast Cancer: The Past, the Present, and the Future
Breast Cancer Research and Treatment
Updated 2013 College of American Pathologists/American Society of Clinical Oncology (CAP/ASCO) Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 (HER2) Fluorescent In Situ Hybridization (FISH) Testing Increase HER2 Positive and HER2 Equivocal Breast Cancer Cases; Retrospective Study of HER2 FISH Results of 836 Invasive Breast Cancers
The Lancet Oncology
Pathological Complete Remission and Long-Term Outcome—What Do We Know in 2016?
New England Journal of Medicine
Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years
Journal of Clinical Oncology
Contemporary Locoregional Recurrence Rates in Young Patients With Early-Stage Breast Cancer
The Lancet Oncology
Neratinib Improves Invasive Disease–Free Survival in HER2-Positive Breast Cancer
The Oncologist
Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer
Clinical Cancer Research
Relationship Between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer
Journal of Oncology Practice
Selection of Optimal Adjuvant Chemotherapy Regimens for Early Breast Cancer and Adjuvant Targeted Therapy for HER2-Positive Breast Cancers: An American Society of Clinical Oncology Guideline Adaptation of the Cancer Care Ontario Clinical Practice Guideline Summary
The Lancet Oncology
Neratinib After Trastuzumab-Based Adjuvant Therapy in Patients With HER2-Positive Breast Cancer (ExteNET): A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial
Journal of Clinical Oncology
Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2–Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3
The Lancet Oncology
Afatinib Plus Vinorelbine Versus Trastuzumab Plus Vinorelbine in Patients With HER2-Overexpressing Metastatic Breast Cancer Who Had Progressed on One Previous Trastuzumab Treatment (LUX-Breast 1): An Open-Label, Randomised, Phase 3 Trial
Videos
Perspectives on the Collaborative Management of HER2-Positive Breast Cancer
Advertisement
Videos
Perspectives on the Collaborative Management of HER2-Positive Breast Cancer
Advertisement
Copyright © 2019 Harborside Press, LLC All rights reserved.
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our
Privacy Policy
to learn more.